Adaptin Bio (APTN) Gains from Investment Securities (2024 - 2026)

Adaptin Bio's Gains from Investment Securities history runs 3 years deep, the most recent figure standing at $247906.0 for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 3827.53% year-over-year to $247906.0; the TTM figure through Mar 2026 stood at $254218.0 (up 992.66% YoY), while the FY2025 annual figure was $54923.0, up 221.43% from the prior year.
• Gains from Investment Securities came in at $247906.0 for Q1 2026 at Adaptin Bio, up from $219693.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $247906.0 in Q1 2026 to a low of $133.0 in Q1 2024.
• A 3-year average of $70142.6 and a median of $6312.0 in 2025 frame the typical range for Gains from Investment Securities.
• On a YoY basis, Gains from Investment Securities climbed as much as 4645.86% in 2025 and fell as far as 3415.65% in 2025.
• Adaptin Bio's Gains from Investment Securities stood at $8332.0 in 2024, then surged by 2536.74% to $219693.0 in 2025, then rose by 12.84% to $247906.0 in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $247906.0, $219693.0, and $6312.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.

Peer Comparison